J.P. Morgan 2020: What To Watch For At The Industry’s Biggest Meeting
Executive Summary
The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.
You may also be interested in...
Gene Therapy Companies Among Top M&A Targets In 2020
Zolgensma shows that a gene therapy can be a commercial hit - but there's still plenty to be wary of in this cutting-edge field.
Sarepta Secures $1.15bn From Roche In Ex-US DMD Gene Therapy Deal
Including upfront payments, half of development costs for SRP-9001, $1.7bn in milestone fees and royalties on sales outside the US, Sarepta pegs deal’s value at $10bn-plus.
Roche/Spark Deal Clears FTC In A Sigh Of Relief For Pharma Dealmakers
US Federal Trade Commission says it conducted an "exhaustive" 10-month investigation and determined Roche would not have incentive to delay the launch of a gene therapy for hemophilia A.